12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

CytRx preclinical data

In a mouse xenograft model of ovarian cancer, 24 mg/kg INNO-206 led to significantly greater reductions in tumor size compared to 8 mg/kg doxorubicin. Additionally, mice treated with 12 mg/kg INNO-206 in combination...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >